Natural History of Stroke: Cause and Development
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00009243|
Recruitment Status : Recruiting
First Posted : January 25, 2001
Last Update Posted : November 22, 2022
The purpose of this study is to learn more about stroke and obtain information that may serve as the basis for future investigations. It will 1) establish a registry of patients with cerebrovascular disease (stroke); 2) characterize the natural history of acute stroke and transient ischemic attacks (TIA) an interruption of blood flow to the brain that causes stroke symptoms for a short period of time); and 3) evaluate the data to generate ideas for future studies.
Patients 18 years of age or older with suspected acute stroke or TIA may be eligible for this study. Subjects will be recruited from patients who present with stroke at the emergency department of Suburban Hospital in Bethesda, Maryland.
The study will gather data collected from diagnostic and laboratory tests the patient undergoes as part of standard medical care, including findings of medical and neurological examinations and other tests. In addition, studies will be done for research purposes only to gather data about stroke and TIA. These may include the following:
- Blood and urine tests not more than 2 tablespoons of blood will be drawn for various tests.
- Electrocardiogram (EKG) (heart tracing) electrodes placed on the chest wall detect the heartbeat and heart rhythm.
- Computed tomography (CT) scan of the head specialized X-rays are used to obtain images of the brain.
- Magnetic resonance imaging (MRI) of the brain a strong magnetic field and radio waves are used to produce images that provide information about the brain tissue and blood vessels.
- Transcranial Doppler (TCD) sound waves are used to image the arteries of the brain and neck.
- Echocardiogram sound waves are used to image the heart and evaluate heart function.
Patients may be asked to return to Suburban Hospital for follow-up testing in 1, 3, and/or 12 months, when some of these tests may be repeated to assess changes over time
|Condition or disease|
|Brain Disease Ischemic Attack, Transient Cerebrovascular Accident Cerebrovascular Disorder Vascular Diseases|
Study Description: This is a natural history/disease pathogenesis protocol for evaluation of patients with or at risk of acute stroke, transient ischemic attack (TIA), or other disturbances of cerebrovascular circulation. The purpose of this protocol is to generate natural history data to serve as the basis for future hypothesis-driven protocols as well as to contribute to the clinical and physiological understanding of cerebrovascular disease through the description of disease manifestation and the relationship among clinical, hematologic, and radiologic variables, as well as identifying potential subjects for future studies on stroke and other cerebrovascular diseases.
- To establish a registry of subjects with cerebrovascular disease including clinical, laboratory, and radiological variables associated with hemorrhagic and ischemic stroke, TIA, and other disturbances of cerebrovascular circulation.
- To characterize the natural history of acute stroke, TIA, and other disturbances of cerebrovascular circulation on these variables.
- To evaluate the relationship among these variables by exploratory analyses and to generate hypotheses for future testing.
- To identify potential subjects for research studies on stroke and other cerebrovascular diseases.
Endpoints: A primary purpose of this observational protocol is to discover and study new imaging biomarkers that are i) relevant to the acute presentation and severity, ii) predictive of clinical outcome, and iii) are useful for stratifying the biological response as reflected in blood-biomarker and gene expression studies. As such, the primary outcome is the results from the imaging studies.
Primary Outcome Measures
Prevalence and type of abnormalities seen on neuroimaging as a function of time from acute insult such as:
Imaging positive for acute ischemic cerebral vascular syndrome ( AICS positive )
Presence of a lesion on diffusion, perfusion, and mismatch between the two
Evidence of a vascular occlusion on MR angiography
Evidence of a thrombus or hemorrhage on T2* GRE imaging
Blood-brain barrier disruption as evidence by HARM 
The evolution of these markers with time and treatment
Secondary Outcome Measures
Stroke severity as measured by NIHSS as a function of time since index event.
Clinical outcome measured using modified Rankin Scale and Barthel Index
Gene expression profiles and biomarker levels obtained from blood samples.
|Study Type :||Observational|
|Estimated Enrollment :||3000 participants|
|Official Title:||Evaluation, Pathogenesis, and Treatment of Patients With or at Risk for Cerebrovascular Disease (A Natural History/Disease Pathogenesis Protocol)|
|Actual Study Start Date :||January 26, 2001|
Patients with acute stroke symptoms
- Prevalence and type of abnormalities seen on neuroimaging as a function of time from acute insult [ Time Frame: Post-acute, 24 hours, 5 days/discharge, 30 days ]Neuroimaging abnormalities, such as:-Imaging positive for acute ischemic cerebral vascular syndrome ( AICS positive )-Presence of a lesion on diffusion, perfusion, and mismatch between the two-Evidence of a vascular occlusion on MR angiography-Evidence of a thrombus or hemorrhage on T2* GRE imaging-Blood-brain barrier disruption as evidence by "HARM"-The evolution of these markers with time and treatment
- Stroke severity as measured by NIHSS as a function of time since index event [ Time Frame: Post-acute, 24 hours, 5 days/discharge, 30 days, 3 months, 6 months, 12 months ]
- Clinical outcome measured using modified Rankin Scale and Barthel Index [ Time Frame: 5 days/discharge, 30 days, 3 months, 6 months, 12 months ]
- Gene expression profiles and biomarker levels obtained from blood samples [ Time Frame: Post-acute, 24 hours, 5 days/discharge, 30 days, 3 months, 6 months, 12 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00009243
|Contact: Mariam Afzal||(301) firstname.lastname@example.org|
|Contact: Lawrence Latour, Ph.D.||(301) email@example.com|
|United States, District of Columbia|
|Medstar Washington Hospital Center||Recruiting|
|Washington, District of Columbia, United States, 20010|
|Contact: Mariam Afzal 240-281-9832 firstname.lastname@example.org|
|United States, Maryland|
|Suburban Hospital - Johns Hopkins Medicine||Recruiting|
|Bethesda, Maryland, United States, 20814|
|Contact: Mariam Afzal 240-281-9832 email@example.com|
|National Institutes of Health Clinical Center||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY dial 711 firstname.lastname@example.org|
|Principal Investigator:||Lawrence Latour, Ph.D.||National Institute of Neurological Disorders and Stroke (NINDS)|